In a report published this week by SPIE — an international not-for-profit society serving more than 256,000 constituents from approximately 155 countries advancing an interdisciplinary approach to the science and application of light — entitled “Laser trapping to show the effects of bacterial arrangement on biofilm infection” (30 December 2014,…
News
As the year 2014 comes to a close, Cystic Fibrosis News Today — your reliable online source for the latest on cystic fibrosis treatments, events, clinical trials, and research updates — has outlined our “Top 14 Cystic Fibrosis Stories of 2014.” The following 14 stories were ranked according to the…
Vertex Pharmaceuticals has just announced the US Food and Drug Administration has granted their lead cystic fibrosis treatment Kalydeco® (ivacaftor) a supplemental new drug application (sNDA). Kalydeco was originally formulated to treat CF in patients aged 6 years and older who carry the…
The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for the commercialization of Quinsair (240 mg) as a therapeutic for adult patients with cystic fibrosis with recurrent infections by Pseudomonas aeruginosa. Cystic Fibrosis (CF) is an inherited disease that is characterized by defective mucus secretions…
A new study entitled “Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices” was published in BMC Microbiology by Juan de Dios Caballero and a group of researchers from Spain. In this study, the authors evaluated the compliance of microbiological procedures…
Clinical-stage biopharmaceutical company N30 Pharmaceuticals, Inc. has named Jon Congleton as the new President and Chief Executive Officer (CEO), as well as a member of the company’s board of directors. Boulder, Colorado-based N30 Pharma is focused on the development of new treatment options for cystic fibrosis (CF), and was the first research company to discover small…
Once dismissed as weakness of human will, chronic depression is increasingly recognized as a legitimate medical problem that is critical to treat. The condition not only affects quality of life, but may also cause additional dire effects on health, specifically in people with cystic fibrosis (CF). German researchers have found that…
Galapagos NV, a developmental stage biotechnology company working on small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic diseases, announced it has launched the first Phase I study of GLPG1837, a potentiator formulated as a CFTR-targeted therapy for cystic fibrosis (CF) cases caused by class III/IV mutations. In order…
Lung transplantation patients who are treated with immune-suppressing drugs after surgery to prevent rejection of the lung are susceptible to contracting life-threatening viruses such as cytomegalovirus (CMV). In order to protect against this, lung transplant patients are normally treated with an anti-viral drug called ganciclovir, which decreases mortality caused…
The Cystic Fibrosis Trust recently announced that it would serve as the official charity partner of the British Comedy Awards for their 25th Anniversary special on December 17, 2014. Before the ceremony officially began, a very special video from the Trust made its debut in front of a star-studded…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.